RIO DE JANEIRO, BRAZIL - The immunizer is in Phase 3 trials in India and is dependent on ANVISA approval to be administered in Brazil. The agency finds no obstacle in the private network application.
The most optimistic scenario estimates that the vaccine will be available in the Brazilian private network in March.
The Brazilian Association of Vaccination Clinics (ABCVAC) reported on Sunday, January 3rd, that it is negotiating with India's Bharat Biotech laboratory the purchase of five million doses of a vaccine against Covid-19.
The immunizer, called Covaxin, had its emergency use in India approved by the country . . .